SCHEMBL4209699

SCHEMBL4209699

CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@@H](OCCCCCCCCCC)[C@H](O)[C@@H](CO[Si](C)(C)C(C)(C)C)O[C@@H]1O

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TLR4 O00206 4/20 0.43
▸ MAPK1 P28482 1/20 0.36
▸ GBA1 P04062 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209695 1.00 TLR4 (0.43) TLR4MAPK1GBA1
SCHEMBL12600842 0.87 TLR4 (0.45) TLR4MAPK1
SCHEMBL12600975 0.87 TLR4 (0.45) TLR4MAPK1
SCHEMBL4191756 0.86 TLR4 (0.46) TLR4MAPK1
SCHEMBL4203583 0.84 GBA1 (0.36) TLR4MAPK1GBA1
SCHEMBL4201760 0.84 TLR4 (0.36) TLR4MAPK1
SCHEMBL4201764 0.84 TLR4 (0.36) TLR4MAPK1
SCHEMBL13296761 0.79 TLR4 (0.39) TLR4MAPK1
SCHEMBL12371590 0.79 TLR4 (0.39) TLR4MAPK1
SCHEMBL4191760 0.78 TLR4 (0.42) TLR4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062214-A1 Left-Side Glucose Lipid a Analogue SANKYO COMPANY, LTD. (JP) 2009-03-05 — — US disclosed
EP-1702926-A1 LEVULOSE GLUCOSELIPID A ANALOGUE Sankyo Company, Limited (JP) 2006-09-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062214-A1 Left-Side Glucose Lipid a Analogue SLC2A3, GPR119, SLC2A2 TLR4 294/4885MAPK1 1294/4885GBA1 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback